VERAXA Biotech AG (NASDAQ: VRXA) has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the company's proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform. This represents an early step in advancing the program toward clinical development.
The company also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026. The data showed that the lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The regulatory feedback from the Paul-Ehrlich-Institute is a critical milestone for VERAXA as it prepares to move its BiTAC-TCE program into clinical trials. The clarity on the non-clinical development plan helps de-risk the path forward, potentially accelerating timelines for first-in-human studies. For patients, this therapy could offer a new treatment option with improved selectivity and safety compared to existing T-cell engagers, which often cause significant side effects due to off-target activation. The BiTAC platform's conditional activity—requiring two targets for activation—may allow for targeting of tumors with higher precision, reducing toxicity to healthy tissues.
The positive preclinical results presented at AACR 2026 further strengthen the case for the BiTAC approach. By demonstrating efficacy comparable to traditional T-cell engagers while sparing single-positive cells, the platform shows promise for a broader therapeutic window. This could potentially enable treatment of cancers that are currently difficult to manage with existing immunotherapies.
For the biotech industry, VERAXA's progress validates the concept of conditionally active bispecific antibodies, a field that has attracted significant interest from major pharmaceutical companies. If successful, the BiTAC platform could lead to a new class of cancer therapies that combine potent T-cell engagement with improved safety. Investors and researchers will be watching for further updates on the non-clinical development and eventual clinical trial initiation.
More information about VERAXA and its BiTAC platform is available in the company's newsroom at http://ibn.fm/VRXA.
